口服抗凝治疗与院内出血并发症及死亡率的关联
该观察性横断面研究纳入2018至2022年74 190例≥18岁住院患者,其中4774例使用DOAC、1768例使用VKA。DOAC与外科患者出血并发症风险降低相关(OR=0.65,95%CI 0.35-0.91),内科患者风险降低无统计学意义(OR=0.59,95%CI 0.33-1.10),两组死亡率风险均无差异。
要点
- 住院患者DOAC使用增加45.11%,DOAC组出血并发症率低于VKA组(1.9%对2.8%)。
- 外科患者使用DOAC与出血并发症风险降低相关(OR=0.65,95%CI 0.35-0.91)。
- 内科患者DOAC出血风险降低无统计学意义,内科与外科死亡率风险均无差异。
核心结论
- 住院患者中DOAC使用增加,且在外科患者中显示对出血并发症的保护作用。
研究设计与样本
- 观察性横断面研究,纳入2018至2022年≥18岁住院患者74 190例,其中DOAC组4774例、VKA组1768例。
主要发现
- 外科患者DOAC使用与出血并发症风险降低相关(OR=0.65;95%CI 0.35-0.91)。
- 内科患者DOAC使用与出血并发症风险降低无统计学意义(OR=0.59;95%CI 0.33-1.10)。
- 内科和外科患者中均未观察到DOAC对死亡率风险的影响。
- 研究期间DOAC使用增加了45.11%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to identify patterns of direct oral anticoagulant (DOAC) and vitamin K antagonist (VKA) use in hospitalized patients and to examine their association with in-hospital haemorrhagic complications and mortality. METHODS: An observational cross-sectional study was conducted among hospitalized patients ≥18 years from 2018 to 2022. Data on hospital discharges were obtained from the minimum data set and were matched with pharmacy records to identify patients treated with DOACs or VKAs. In-hospital haemorrhagic complications and mortality rates were calculated for study groups. Multivariate logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (95%CIs), adjusting for age, sex and comorbidities. Analyses were stratified by medical and surgical profiles. Statistical significance was set at .05. RESULTS: The study included 74 190 patients, with 4774 receiving DOACs and 1768 VKAs. During the study period, DOAC use increased by 45.11%. DOAC-treated patients had lower complication rates than those treated with VKAs (1.9 vs. 2.8%, respectively; P = .032). DOAC use was linked to a lower risk of haemorrhagic complications in surgical patients (OR = 0.65; 95%CI: 0.35-0.91), while in medical patients, the reduction in risk was not statistically significant (OR = 0.59; 95%CI: 0.33-1.10). No effect on mortality risk was observed among medical and surgical patients. CONCLUSIONS: The increased use of DOACs among hospitalized patients showed a protective effect against haemorrhagic complications in surgical patients, supporting their increasing use in hospital settings.
引用
- Lagrave J, Domingo L, Barceló-Vidal J, et al. Association between oral anticoagulant therapy and in-hospital complications and mortality. Br J Clin Pharmacol. 2025. PMID: 40331313. doi:10.1002/bcp.70087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。